CEL-SCI Corporation news

   Watch this stock
Showing stories 1 - 10 of about 87   

Articles published

CVM 1.77 -0.06 (-3.28%)
price chart
Cel-Sci Corporation: The Arbitration Is On, But Is The Phase III Trial Off?
I've gone through fur or five significant redrafts of this article since I started trying to get it organized at the end of August, and each time I thought I had captured a good representation of the current situation for Cel-Sci Corp. (NYSEMKT:CVM ...
CEL-SCI Corp (CVM) Granted European Patent for Multikine's Mechanism of Action ...
CEL-SCI Corporation (NYSE: CVM) announced today that the European Patent Office has issued a new patent to CEL-SCI for its lead investigational immunotherapy, Multikine* (Leukocyte Interleukin, Injection), which is currently in a pivotal Phase 3 trial ...
The Fundamental Case for and Against CEL-SCI Corporation (CVM)  StockNewsGazette
A Few Clear Signs for CEL-SCI Corporation (CVM)  StandardOracle
CEL-SCI Corporation Releases Letter to Shareholders
CEL-SCI initiated the proceedings against the former CRO in October 2013 and is seeking payment for damages related to the former CRO's prior involvement in the Phase 3 clinical trial of Multikine.
CEL-SCI Corp (CVM) Says FDA Requested Changes to Multikine Investigator Brochure
On June 28, 2017 CEL-SCI Corporation received a letter from the U.S. Food and Drug Administration (FDA) in response to CEL-SCI's most recent June 2, 2017 submission regarding the clinical hold imposed on the Company's Phase 3 head and neck cancer ...
Eye-Catching Hot Stocks: CEL-SCI Corporation (NYSE: CVM)
On Monday, Shares of CEL-SCI Corporation (NYSE: CVM) expressed a change of -0.55% and is currently trading at $1.82. The stock exchanged hands with 42,373 numbers of shares compared to its average daily volume of 216.15K shares.
Analyst Stock Recommendations For Ternium SA (TX), CEL-SCI Corporation ...  Analyst Journal
CEL-SCI Announces Reverse Stock Split
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) announced today that during its annual Shareholder's Meeting on June 12, 2017, a 1-for-25 reverse split was authorized for its outstanding shares of common stock.
Vienna's Cel-Sci Corp. raises $1 million for head and neck cancer trial
Vienna-based drug company Cel-Sci Corp. raised $1 million from institutional investors in a direct offering of 10 million shares, a Securities and Exchange Commission filing this week shows.
Analysts Layout Best- And Worst-Case Scenarios: Aduro BioTech, Inc. (ADRO ...
Aduro BioTech, Inc. (NASDAQ:ADRO) recent decline occurred on low volume with 0.37 million contracts changing hands on 13-Oct-17. That's down from its daily average of 0.4 million contracts.
A Technical Look into the Valuation For CEL-SCI Corporation (AMEX:CVM)
Here we will take a look at several key ratios for CEL-SCI Corporation (AMEX:CVM), starting with the Book to Market (BTM) ratio.
Is CEL-SCI Corporation (NYSEMKT:CVM) About To Get An FDA Resolution?
CEL-SCI Corporation (NYSEMKT:CVM) has had a noteworthy run year to date. The company started out 2017 at around $0.07 a share, and has since gained to trade above $0.11 - a 60% gain across the period.
The Saga Of CEL-SCI Corporation (NYSEMKT:CVM)'S Bleak Clinical Trials  Journal Transcript